Cost-utility analysis of implementing early genetic screening programs for hereditary cancer (e.g., BRCA mutations) in the compulsory medical insurance system
It was found that preventing breast and ovarian cancer or detecting it at early, localized stages provides significant long-term savings for the compulsory health insurance system by reducing treatment costs for disseminated forms of the disease and leads to a significant increase in QALYs saved.